AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9513613
Drug: Oral 17
RxNorm normalized name: polyoxypropylene (17)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17 beta estradiol 2 mg per day
Trial: 9513613
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta estradiol 50 micrograms per day
Trial: 8678131
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 0.625 mg per day
Trial: 9513613
Drug: 17 beta
RxNorm normalized name: 17 beta-estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta estradiol gel 1.5 micrograms per day
Trial: 9513613
Drug: Delayed estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed estrogen replacement therapy (at 65 years of age)
Trial: 8498533
Drug: Bromocriptine (BRC)
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine (BRC) 1.25 mg per os
Trial: 3591727
Drug: Aquabiosorb soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquabiosorb soft elastic gelatin (SEG) capsule
Trial: 3591727
Drug: modified standard‐SEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified standard‐SEG capsule
Trial: 3591727
Drug: commercial tablet
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: commercial tablet
Trial: 3591727
Drug: SEG formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEG formulation
Trial: 28272972
Drug: Solution‐Focused Coaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution‐Focused Coaching in pediatric rehabilitation (SFC‐Peds)
Trial: 26638119
Drug: Memantine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (10 mg/day)
Trial: 22219334
Drug: Intravenous colloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous colloid volume loading (11 ml kg⁻¹) during heat stress
Trial: 20303444
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of DTaP‐HBV‐IPV/Hib at 12 to 23 months
Trial: 17012885
Drug: Active specific
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active specific immunotherapy with autologous tumor cell vaccines
Trial: 14614670
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin (500 mg/day) for 2-7 days, followed by oral azithromycin (1500 mg over 3 or 5 days)
Trial: 10908823
Drug: Controlled-release metoclopramide
RxNorm normalized name: metoclopramide Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release metoclopramide 40 mg every 12 hours
Trial: 8694208
Drug: 1% propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% propofol infusion at 0.1 ml.kg‐1.h‐1 for 24 h after surgery
Trial: 8694208
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid infusion at 0.1 ml.kg‐1.h‐1 for 24 h after surgery (Control)
Trial: 4070323
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pivmecillinam plus 250 mg pivampicillin given twice daily
Trial: 4070323
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg amoxycillin given 3-times daily
Trial: 31906751
Drug: Dexmedetomidine 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg + 0.25 mcg/kg/h (group D1)
Trial: 31906751
Drug: Dexmedetomidine 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg + 0.5 mcg/kg/h (group D2)
Trial: 31906751
Drug: Dexmedetomidine 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg + 1 mcg/kg/h (group D3)
Trial: 30485853
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin (atorvastatin 60 mg/day, adjusted to 20 mg/day after 7 days)
Trial: 30485853
Drug: Control (atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (atorvastatin 20 mg/day)
Trial: 28302075
Drug: Zinc (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (60 mg) administration
Trial: 16176203
Drug: Hyperglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (blood glucose level at 16 mmol/l for 3 hours)
Trial: 16176203
Drug: Normoglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycaemia (blood glucose level at 5 mmol/l for 3 hours)
Trial: 12591750
Drug: ivabradine 5
RxNorm normalized name: ivabradine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 5 mg BID
Trial: 12591750
Drug: ivabradine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 10 mg BID
Trial: 8678158
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel (4 mg, 2 applications 4 hours apart)
Trial: 6352601
Drug: Azlocillin at
RxNorm normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azlocillin at 8 g/day
Trial: 6352601
Drug: Ticarcillin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin at 12 g/day
Trial: 24703486
Drug: Physiologic replacement-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic replacement-dose recombinant human leptin (metreleptin)
Trial: 24703486
Drug: Leptin treatment
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin treatment in vitro
Trial: 11368138
Drug: Uterine artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterine artery Doppler screening followed by 100 mg of aspirin daily until the 35th week
Trial: 11368138
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Doppler screening and no aspirin treatment)
Trial: 8508709
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (tetracycline hydrochloride 500 mg four times a day for days 0-14 and metronidazole 500 mg three times a day for days 15-28)
Trial: 8508709
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (120 mg four times a day for 8 weeks)
Trial: 8508709
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy offered to six patients on bismuth whose ulcers remained unhealed or relapsed early after healing
Trial: 3729081
Drug: Transdermal azatadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal azatadine maleate TDDS
Trial: 3729081
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral doses of azatadine
Trial: 29783269
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen + paracetamol (n = 12)
Trial: 29783269
Drug: Ibuprofen +
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen + placebo (n = 12)
Trial: 24523037
Drug: High-sensitivity C-reactive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity C-reactive protein (hsCRP) levels in the top quartile (hsCRP>4.86 mg/L)
Trial: 21116018
Drug: Aromatase and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase and 5α-reductase inhibitor (AI) 500 mg once per day for 8 weeks
Trial: 21116018
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) 500 mg once per day for 8 weeks
Trial: 15654581
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (all doses combined)
Trial: 12877450
Drug: Diskus (inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diskus (inhalation powder)
Trial: 12877450
Drug: MDI (inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI (inhalation aerosol)
Trial: 10486466
Drug: Norethindrone 24
RxNorm normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethindrone 24 hours before gonadotropin-releasing hormone agonist therapy
Trial: 10486466
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist alone
Trial: 29021299
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR standard dose (2 108 CFU)
Trial: 29021299
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR high dose (2 109 CFU)
Trial: 29021299
Drug: Shanchol inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shanchol inactivated cholera vaccine (two doses)
Trial: 29021299
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR high dose
Trial: 19252811
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg daily for 2 years
Trial: 2773628
Drug: H2 blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H2 blockers (Ranitidine and Cimetidine)
Trial: 31642984
Drug: Phytosterols-enriched soya
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterols-enriched soya drink (2 g of phytosterol per day)
Trial: 30354023
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment (12 weeks) with spinal manipulative therapy (SMT) and supervised rehabilitative exercises (SRE)
Trial: 30354023
Drug: Long-term management
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term management (36 weeks) with spinal manipulative therapy (SMT) and supervised rehabilitative exercises (SRE)
Trial: 21071096
Drug: Active compounds
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active compounds (aripiprazole, lamotrigine, olanzapine/olanzapine-fluoxetine, quetiapine)
Trial: 16729779
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray once daily
Trial: 16729779
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium nasal spray 3 times daily
Trial: 11174592
Drug: Topical amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical amoxicillin (3 g per mouthwash rinse)
Trial: 11174592
Drug: Standard prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylaxis with oral amoxicillin (3 g in a single dose)
Trial: 8324872
Drug: Epirubicin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 150 mg/m2
Trial: 8324872
Drug: Epirubicin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 75 mg/m2 vs 150 mg/m2
Trial: 3553878
Drug: Low-dose levodopa-carbidopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose levodopa-carbidopa therapy
Trial: 15219176
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol 250/50 microg twice daily via DISKUS
Trial: 15219176
Drug: Ipratropium bromide/albuterol
RxNorm normalized name: ipratropium bromide/albuterol sulfate 0.5 mg-2.5 mg/2.5 mL INHALATION VIAL, NEBULIZER (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide/albuterol 36/206 microg four times daily via metered‐dose inhaler
Trial: 11201511
Drug: Sequential combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combined oral 17beta-estradiol norethisterone acetate
Trial: 7875638
Drug: Pinacidil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil (25 mg, sustained-release form)
Trial: 3277476
Drug: Topical antibiotics
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotics alone (22 patients)
Trial: 3277476
Drug: Cefoxitin and
RxNorm normalized name: CEFOXITIN SODIUM 1 g in 50 mL INTRAVENOUS INJECTION, SOLUTION [Cefoxitin and Dextrose]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin and topical antibiotics (24 patients)
Trial: 3277476
Drug: Penicillin, tobramycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin, tobramycin, clindamycin, and topical antibiotics (23 patients)
Trial: 29309346
Drug: Detectable UPLC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detectable UPLC (≥25 to <1000 μg/l)
Trial: 29309346
Drug: Undetectable UPLC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undetectable UPLC (<25 μg/l)
Trial: 29309346
Drug: Suboptimal UPLC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboptimal UPLC (≥25 to <1000 μg/l)
Trial: 24237037
Drug: Individualised dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised dosing of azathioprine (AZA) starting at 1.0 mg/kg/day (if intermediate TPMT) or 2.5 mg/kg/day (if normal TPMT), adjusted to target 6TGN concentrations of 250-400 pmol/8 × 10(8) RBC.
Trial: 24237037
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing of azathioprine (AZA) at 2.5 mg/kg/day.
Trial: 24237037
Drug: Individualised dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised dosing of azathioprine (AZA) in per-protocol analysis.
Trial: 24237037
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing of azathioprine (AZA) in per-protocol analysis.
Trial: 19083413
Drug: Increase of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase of 100 g/d of vegetables
Trial: 19083413
Drug: Increase of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase of 100 g/d of fruits
Trial: 21362332
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab (1.25 mg/0.05 ml)
Trial: 21362332
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 ml) combined with triamcinolone acetonide (2 mg/0.05 ml)
Trial: 17201798
Drug: Low-dose hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose hormone replacement therapy (HRT) with continuous oral 17beta oestradiol (1 mg) and norethisterone (0.5 mg)
Trial: 17201798
Drug: Low-dose hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose hormone replacement therapy (HRT)
Trial: 15138953
Drug: Oral olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral olanzapine (10 mg per day, increased to 20 mg per day by day 3)
Trial: 15138953
Drug: Oral haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral haloperidol (10 mg per day)
Trial: 9972673
Drug: Low-dose bedtime
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bedtime NPH insulin
Trial: 9972673
Drug: t.i.d. oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t.i.d. oral metformin
Trial: 5321762
Drug: Isoniazid (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (5-10 mg per kg of body-weight in one daily dose)
Trial: 25961145
Drug: End-of-treatment self-efficacy
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-of-treatment self-efficacy
Trial: 12799555
Drug: Atazanavir 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 400 mg/saquinavir 1200 mg once daily
Trial: 12799555
Drug: Atazanavir 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 600 mg/saquinavir 1200 mg once daily
Trial: 12799555
Drug: Ritonavir/saquinavir 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir/saquinavir 400 mg/400 mg twice daily
Trial: 10430107
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg saquinavir (Fortovase soft-gel capsule formulation)
Trial: 7762534
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (60 mg, 200,000 IU every 4 months)
Trial: 2193856
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 x 1 g/day)
Trial: 2193856
Drug: Cefotaxime (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (3 x 1 g/day)
Trial: 30773747
Drug: CHM-diet (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHM-diet (2% Chinese herbal medicine)
Trial: 28128473
Drug: Intra-articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronic acid (HA) injections (HAnox-M or BioHA), 3 weekly injections
Trial: 28128473
Drug: Intra-articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronic acid (HA) injections (HAnox-M or BioHA)
Trial: 23856172
Drug: C+L+ (Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+L+ (Caffeine 200mg + Bright light 10,000 lux)
Trial: 23856172
Drug: C‐L‐ (Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐L‐ (Caffeine placebo + Bright light placebo <50 lux)
Trial: 19317898
Drug: Dignity Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity Therapy offered in addition to standard care
Trial: 16681811
Drug: Traditional antimycotic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional antimycotic treatment
Trial: 8405018
Drug: Diclofenac dispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac dispersible (50 mg)
Trial: 3806488
Drug: Established treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established treatment for hypertension interrupted by placebo
Trial: 31081595
Drug: Immediate allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate allopurinol dose escalation to SU target
Trial: 31081595
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing for 1 year followed by dose escalation to target (Control)
Trial: 29210625
Drug: Serum-derived bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum-derived bovine immunoglobulin/protein isolate (SBI) at 2.5 or 5.0 g BID for 4 weeks
Trial: 29210625
Drug: Serum-derived bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum-derived bovine immunoglobulin/protein isolate (SBI) at 2.5 or 5.0 g BID
Trial: 7999809
Drug: Intramuscular rHuEpo
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular rHuEpo
Trial: 7999809
Drug: Subcutaneous rHuEpo
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rHuEpo
Trial: 29300256
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 mL of intraurethral aqueous gel)
Trial: 25917337
Drug: 60-second delayed
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-second delayed therapy in the VT zone 170-199 bpm (arm C)
Trial: 21985746
Drug: Caries preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caries preventive package (fluoride varnish twice per year for three years, fluoride toothpaste 1,450 ppm F supplied twice per year, toothbrush supplied twice a year, plus standardised dental health education)
Trial: 19935992
Drug: Percutaneous adhesiolysis
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non‐particulate Betamethasone.